Skip to Content

Unituxin (dinutuximab) Disease Interactions

There are 9 disease interactions with Unituxin (dinutuximab):

Major

Antineoplastics (Includes Unituxin) ↔ Infections

Severe Potential Hazard, Moderate plausibility

Applies to: Infection - Bacterial/Fungal/Protozoal/Viral

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Novantrone (mitoxantrone)." Immunex Corporation, Seattle, WA.
  2. "Product Information. Doxil (doxorubicin liposomal)." Sequis Pharmaceuticals Inc, Menlo Park, CA.
  3. "Product Information. Fludara (fludarabine)." Berlex, Richmond, CA.
  4. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company, Indianapolis, IN.
  5. Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992): 1396-7
  6. "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb, Princeton, NJ.
  7. "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.
  8. "Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.
  9. "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb, Princeton, NJ.
  10. "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  11. "Product Information. Alkeran Tablets (melphalan)." Glaxo Wellcome, Research Triangle Pk, NC.
  12. Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990): 833-4
  13. "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.
  14. "Product Information. Hycamtin (topotecan)." SmithKline Beecham, Philadelphia, PA.
  15. "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.
  16. "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn, Kalamazoo, MI.
  17. "Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome, Research Triangle Pk, NC.
  18. "Product Information. Platinol (cisplatin)." Bristol-Myers Squibb, Princeton, NJ.
  19. Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992): 314-5
  20. "Product Information. Methotrexate (methotrexate)." Lederle Laboratories, Wayne, NJ.
  21. Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994): 407-8
  22. "Product Information. Xeloda (capecitabine)." Roche Laboratories, Nutley, NJ.
  23. "Product Information. Vepesid (etoposide)." Bristol-Myers Squibb, Princeton, NJ.
  24. "Product Information. Tabloid (thioguanine)." Glaxo Wellcome, Research Triangle Park, NC.
  25. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  26. "Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation, Eatontown, NJ.
  27. "Product Information. Nipent (pentostatin)." Parke-Davis, Morris Plains, NJ.
  28. "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb, Princeton, NJ.
  29. "Product Information. DTIC-Dome (dacarbazine)." Bayer, West Haven, CT.
  30. "Product Information. Thiotepa (thiotepa)." Lederle Laboratories, Wayne, NJ.
  31. Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991): 671
View all 31 references
Major

Monoclonal Antibodies (Includes Unituxin) ↔ Infusion Reactions

Severe Potential Hazard, Moderate plausibility

Applies to: Hypotension, Pulmonary Impairment, Angioedema, Urticaria, Hypertension

The use of monoclonal antibodies administered via IV infusion may cause serious infusion reactions, including bronchospasm, hypoxia, dyspnea, fluctuations in blood pressure, laryngeal edema and pulmonary edema. Caution should be taken in patients with a history of cardiopulmonary disease as they may require additional post-infusion medications to manage respiratory complications. It is recommended to administer required intravenous hydration and premedication with antihistamines, analgesics, and antipyretics before administration. Monitor closely for signs and symptoms of infusion reactions during and for at least 4 hours following completion of each infusion in a setting where cardiopulmonary resuscitation medication and equipment are available. Immediately interrupt or permanently discontinue treatment and institute supportive management for severe or prolonged infusion reactions as appropriate.

Major

Monoclonal Antibodies (Includes Unituxin) ↔ Tumor Lysis Syndrome

Severe Potential Hazard, Moderate plausibility

Applies to: Tumor Lysis Syndrome

Tumor lysis syndrome (TLS) has occurred in patients receiving certain monoclonal antibodies. Patients with high tumor burden and those with high circulating lymphocyte counts of greater than 25 X 10^9/L have a higher risk of developing TLS. Consider tumor lysis prophylaxis prior to the infusion with anti-hyperuricemics and hydration beginning 12 to 24 hours prior to infusion. It is recommended to correct electrolytes abnormalities, and monitor renal function in patients who develop TLS. Monitor for signs and symptoms of TLS and temporary interruption or discontinuation of therapy might be required.

Moderate

Dinutuximab (Includes Unituxin) ↔ Electrolytes Abnormalities

Moderate Potential Hazard, Moderate plausibility

Applies to: Electrolyte Abnormalities

Dinutuximab can cause electrolytes abnormalities, including hypokalemia, hyperkalemia, hypocalcemia, and hyponatremia. Electrolyte abnormalities should be corrected prior to initiating nilotinib and should be monitored daily during therapy.

Moderate

Dinutuximab (Includes Unituxin) ↔ Hemolytic Uremic Syndrome

Moderate Potential Hazard, Moderate plausibility

Applies to: Hemolytic Uremic Syndrome

Atypical hemolytic uremic syndrome in the absence of documented infection and resulting in renal insufficiency, electrolyte abnormalities, anemia, and hypertension can occur in patients treated with dinutuximab. Atypical hemolytic uremic syndrome has recurred following rechallenge with dinutuximab. Permanently discontinue therapy and institute supportive management for signs of hemolytic uremic syndrome.

Moderate

Dinutuximab (Includes Unituxin) ↔ Hypotension

Moderate Potential Hazard, Moderate plausibility

Applies to: Hypotension

Hypotension has been observed during therapy with dinutuximab. This drug should be used with caution, especially in patients with tendency towards hypotension or taking other drugs known to cause hypotension. It is recommended to administer required intravenous hydration prior to each infusion and to closely monitor blood pressure during treatment. Interruption or discontinuation of treatment might be necessary if systolic blood pressure is less than lower limit of normal for age, or if it decreases by more than 15% compared to baseline.

Moderate

Dinutuximab (Includes Unituxin) ↔ Myelosuppression

Moderate Potential Hazard, Moderate plausibility

Applies to: Bone Marrow Depression/Low Blood Counts

Myelosuppression has been reported during administration of dinutuximab . In a clinical study, severe thrombocytopenia, anemia, neutropenia occurred more frequently in patients treated with dinutuximab/13-cis-retinoic acid group compared to those treated with 13-cis-retinoic acid alone. Therapy with rituximab should be administered cautiously in patients with severe bone marrow suppression. Clinical monitoring of hematopoietic function is recommended during therapy.

Moderate

Dinutuximab (Includes Unituxin) ↔ Neurotoxicity

Moderate Potential Hazard, Moderate plausibility

Applies to: Peripheral Neuropathy, Urinary Retention, Neurologic Disorder

Dinutuximab causes serious neurologic adverse reactions including, severe neuropathic pain, peripheral neuropathy, neurologic disorders of the eye, prolong urinary retention, and transverse myelitis. Discontinue treatment for severe unresponsive pain, severe sensory neuropathy, and moderate to severe peripheral motor neuropathy. It might be necessary to permanently discontinue treatment in certain cases. Care should be exercised when prescribing this agent to patients at risk for neurotoxicity. It is recommended to administer required intravenous hydration and premedication with antihistamines, analgesics, and antipyretics before administration.

Moderate

Dinutuximab (Includes Unituxin) ↔ Posterior Leukoencephalopathy Syndrome

Moderate Potential Hazard, Moderate plausibility

Applies to: Posterior Reversible Encephalopathy Syndrome

The use of dinutuximab may cause reversible posterior leukoencephalopathy syndrome (RPLS). Caution and close monitoring is advised when prescribing this agent to patients at risk of RPLS. It is recommended to administer appropriate treatment and discontinue therapy if RPLS is suspected.

Unituxin (dinutuximab) drug Interactions

There are 3 drug interactions with Unituxin (dinutuximab)

Unituxin (dinutuximab) alcohol/food Interactions

There is 1 alcohol/food interaction with Unituxin (dinutuximab)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide